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Abstract
Background: Paracetamol’s solubility is achieved by adding to the excipient sodium salts, either as bicarbonate,
carbonate or citrate. As the relationship between salt and hypertension is well known, due to the sodium content it
has raised a hypothesis that may interfere with the control of that risk factor.
Therefore, the objective of this study is to evaluate the effect on blood pressure of effervescent paracetamol
compared to non-effervescent, in hypertensive patients.
Methods/Design: This is the protocol of a phase IV multicenter clinical trial, randomized, controlled, crossover,
open, which will compare the effect of two different formulations of paracetamol (effervescent or non-effervescent)
in the blood pressure of hypertensive patients, with a seven weeks follow up.
49 controlled hypertensive patients will be included (clinical BP lower than 150 and 95 mmHg, and lower than
135 mmHg and 85 mmHg in patients with diabetes or a history of cardiovascular event, and daytime ambulatory
measurements lower than 140 and 90 mmHg) and mild to moderate pain (Visual Analog Scale between 1 and 4).
The study was approved by the ethics committee of the Fundació Jordi Gol i Gurina and following standards of
good clinical practice.
The primary endpoint will be the variations in systolic BP in 24 h Ambulatory Blood Pressure Monitoring, considering
significant differences 2 or more mmHg among those treated with non-effervescent and effervescent formulations.
Intention-to-treat and per-protocol analysis will be held.
Discussion: Despite the broad recommendation not to use effervescent drugs in patients with hypertension, there are
relatively little studies that show exactly this pressor effect due to sodium in salt that gives the effervescence of the
product.
This is the first clinical trial designed to study the effect of effervescence compared to the non-effervescent,
in well-controlled hypertensive patients with mild to moderate pain, performed in routine clinical practice
Trial registration: NCT 02514538
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Background
Hypertension control has become a prime target because
of its significant relationship to cardiovascular disease
(1–3). At the same time, musculoskeletal diseases are
among the leading causes of analgesics prescription (4).
It is known that the continued use of nonsteroidal
anti-inflammatory drugs (NSAIDs) carries a high risk of
side effects, including difficulty in controlling hyperten-
sion (5–7). Therefore paracetamol seems the best option
for hypertensive patients requiring analgesia (7).
However, in some studies it has been observed that
paracetamol can also be associated with an increase
in BP, increasing the risk of hypertension or hindering
its control, although there is no consensus on this
issue (8–13).
Moreover, one of the most common forms of presen-
tation of paracetamol is soluble, which appears to in-
crease the absorption rate, reduce the time of onset of
action and facilitates its administration when there are
intake difficulties.
Solubility of paracetamol is achieved by adding to the
excipient salts containing sodium, either as bicarbonate,
carbonate or citrate. As the relationship between salt
and hypertension is well known, due to the sodium con-
tent it has raised a hypothesis about whether these pre-
sentations could interfere in the control of hypertensive
patients or favor the emergence of new cases of hyper-
tension. There are some observational studies, although
few patients included, which seem to support this rela-
tionship between consumption of effervescent formula-
tions and the difficulty of hypertension control (14, 15)
Such small samples, the potential confounders not in-
cluded in the studies such as patients’ pain, the possible
phenomenon of regression to the mean, and data from
other studies that contradict this hypothesis (16–21)
make the existence of more studies needed, with the ex-
press purpose of seeing the effect of effervescent para-
cetamol on BP.
Methods/Design
Objectives and hypothesis
Objectives
The overall aim of the study is to evaluate the pressor ef-
fect of effervescent paracetamol formulation compared
to the formulation of non-effervescent paracetamol in
hypertensive patients.
Hypothesis
The effervescent preparations normally don’t contain
sodium chloride (salt directly related to BP), but con-
tain other salts. So, we hypothesize that hypertensive
patients treated with effervescent paracetamol should
not present BP higher than those taking formulations
non-effervescent.
Study design
This is a multicenter, randomized, controlled, crossover,
open, phase IV clinical trial, which compares the effect
of two different formulations of paracetamol (efferves-
cent or non-effervescent tablets) in the blood pressure
of hypertensive patients after 3 weeks treatment (coded
EUDRACT 2010-023485-53). The washout period be-
tween the two treatment periods is approximately 1 week
(minimum 3 days).
Setting
The study will be conducted in Primary Care, with the
participation of 13 primary care centers in Catalonia and
Euskadi. The study protocol was approved by the Ethics
Committee of IDIAP Jordi Gol and the rules of good
clinical research practice will be followed.
Study population
Inclusion criteria
Patients included in the study must meet the following
criteria:
– be hypertensive patients over 18 years
– with chronic osteoarticular disease
– which regularly need analgesic treatment.
They must submit BP in the consultation lower than
150 and 95 mmHg or lower than 135 and 85 mmHg if
they have associated cardiovascular disease (stroke, cor-
onary heart disease, peripheral arterial disease) or dia-
betes mellitus.
Antihypertensive treatment must be stable and un-
changed in the last month, or patients should be con-
trolled without drugs. In relation to chronic
osteoarticular disease, they should have a degree of
mild to moderate pain, with a score between 1 and 4
on a VAS.
Exclusion criteria
Patients with allergy, intolerance or contraindication
to paracetamol or tramadol will be excluded, as
those who have taken NSAIDs orally or parenterally
in the last week, or have a high degree of pain
(VAS > 4) or poorly controlled hypertension (office
BP > 150/95 mmHg or daytime ambulatory mean
BP > 140/90 mmHg).
Patients with heart failure due to systolic and / or
diastolic dysfunction will also be excluded, those
who have suffered a cardiovascular event (myocardial
infarction, unstable angina or stroke of any type) in
the last 6 months, presenting sleep apnea or any
form of secondary hypertension, elevated transami-
nases (higher than 3 times normal value), or a glom-
erular filtration rate <30 ml/min, over a maximum
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period of three months before starting the study; pa-
tients with dementia or judicial disability, with alco-
holism or other addictions; pregnant patients;
patients treated with oral anticoagulants or subcuta-
neous heparin. Patients in which changes are fore-
seen in usual dose drugs with effects on BP
throughout the study (alpha blockers, tricyclic anti-
depressants, beta blockers in eye drops, sympatho-
mimetic vasoconstrictor, other effervescent agents,
hormonal contraceptives, NSAIDs, corticosteroids,
anabolic, erythropoietin, cyclosporine) or those who
will initiate major changes in lifestyles (onset or in-
crease physical exercise, dietary changes); those who
do not give their informed consent and that in the
opinion of the investigator, have poor adherence or
may become lost to follow-up.
Recruitment process
Patients meeting the inclusion criteria will be identified
using the electronic medical record systems, OSABIDE
in Osakidetza and the SISAP in the Catalan Health Ser-
vice. Considering the information in the medical record,
each doctor will check the list of candidate patients,
rejecting those that a priori meet any of the exclusion
criteria, that is, cases in which inappropriate patients
have been identified by the electronic selection’ process.
Participating physicians may also include patients who
met inclusion criteria, but for some reason were not se-
lected by the selection system.
Once elected, it will be proposed to patients to par-
ticipate in the trial, giving writing information and
requesting written informed consent, after a first visit
for confirmation of all the inclusion criteria and none
of exclusion.
In addition, a blood test assessing complete blood
count, kidney and liver function will be performed to all
patients who do not have one including all these param-
eters in the previous 3 months.
Washout period
A 3 to 7 days washout period for paracetamol will pre-
cede randomization. During this washout period, the an-
algesic treatment will be tramadol when necessary.
Randomization
Patients who met all inclusion criteria and none of the
exclusion will be assigned through centralized, automatic
and masked randomization, for successive scrambling.
Patients will be allocated through an electronic case re-
port form (CRF) to the first of two treatment sequences
to follow: AB or BA.
A: Effervescent Paracetamol (Termalgin ® envelopes) at
doses of 1000 mg / 8 h
B: Paracetamol in non-effervescent tablets (Kern
pharma ® Paracetamol 1 g), at doses of 1000 mg / 8 h.
Intervention
The initial paracetamol dose is 1000 mg every 8 h. If
the pain is not controlled (VAS > 3), tramadol will be
administered at doses between 50 i 150 mg / day, at
the discretion of the investigator.
Rescue analgesia chosen is tramadol, following the
NICE Osteoarthritis Guide recommendations, which
ranks in the second therapeutic step (4).
The medications in this trial are marketed and will be
procured in Spain and conditioned (labeled only for use
in clinical trials) according to the standards of Good
Manufacturing Practice for medicinal products.
To assess compliance, counting tablets or sachets dis-
pensed will be held in each subsequent visit to dispens-
ing medication. It will be considered adequate if it is
between 80 and 110 %.
BP must be measured in both arms at first visit,
subsequent blood pressures measures will be per-
formed in the arm with the higher reading. These
measures must be done with the person seated and
standing, and using an appropriate cuff size for the
person’s arm. For ambulatory blood pressure monitor-
ing (ABPM) validated SpaceLabs 90207 (22) or Micro-
life Watch BP (23) devices will be used, and will be
considered valid those with 60 % or more valid read-
ings, or at least 20 daytime readings and 8 nocturnal,
as recommended by the latest guidelines (24).
Figures 1 and 2 show the flow chart diagram and visit
schedule.
Evaluation of results
Primary endpoint
The primary endpoint is the change in mean daytime,
night-time (sleep) and 24-h systolic BP, measured by
ABPM, from baseline at 3 weeks of treatment in both
periods.
Secondary endpoints
– Changes in systolic BP measured in the clinic at the
end of 3-week follow-up respect baseline in both
periods.
– 24-h, daytime and night-time (sleep) diastolic BP
measured by ABPM: change from baseline at 3 weeks
of treatment in both periods
– Changes in diastolic BP measured in the clinic at the
end of 3-week follow-up respect baseline in both
periods.
– Percentage of patients maintaining clinical BP under
140 and 90 mmHg at the end of each period
– Degree of pain assessed by visual analog scale
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– Consumption of rescue medication
– Therapeutic compliance
Adverse effects
Mild adverse events occurring during the study will be
collected in the case report form, indicating the likeli-
hood that may be related to drugs; if serious adverse re-
actions occur they will be immediately notified to the
responsible for pharmacovigilance.
Sample size
49 patients are required to detect a difference in systolic
BP equal to or greater than 2 mmHg in 24-h systolic BP
detected by ABPM (minimum difference with relevance
in clinical practice), with a standard deviation of the
mean difference of 4.5 mmHg (14), and for a crossover
design. An alpha error of 5 % and beta error of 20 % in a
two-tailed test, and maximum loss rate of 15 % is
assumed.
Statistical analyses
The analysis will be carried out on an intention-to-treat
basis, comparing the mean blood pressure at the end of
the period with that observed at initial time, adjusting
for the baseline blood pressure at the start of each
period in all patients which at least have received one
dose of treatment. Moreover, we will perform a per
protocol analysis with only the patients who have not
changed their treatment within the 7-weeks of the trial
and have not been withdrawn.
Categorical variables will be presented using frequen-
cies and percentages whereas that continuous variables
will be presented using the mean, median, standard devi-
ation, minimum, maximum, interquartile range and
number of subjects under observation. All statistical
Fig. 1 Flow chart
Fig. 2 Visit schedule. * If none in the previous 3 months
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tests are going to be two-tailed tests with an α level of
0.05, obtaining confidence intervals of 95 %.
To analyze the differences between drugs in BP change
between the beginning and the end of treatment, an
ANOVA model will be used with the period, sequence,
treatment and subject factors, declaring random factor
subject nested within sequence. From this model estima-
tors of the difference between the two formulations with
confidence intervals to 95 % will be obtained.
For all other variables the following strategy is to be
used: to compare categorical variables intragroup McNe-
mar’s test will be used, for continuous variables
dependent Student’s t-test. If not met the assumptions of
applicability, nonparametric methods (Wilcoxon test)
will be used.
We will adjust for potential confounding or modifying
variables: age, sex, comorbidity as diagnosis of dyslipid-
emia, diabetes, stroke, Peripheral artery disease or myo-
cardial infarction.
In the mixed-effect analysis, all the data available from
each of the subjects included in the study will be consid-
ered, regardless of whether there is missing data. Values
of missing data will not be imputed, except in the case
of the baseline values for the second period, in which
case they will be assigned the same value as the baseline
measurements at the start of the study. It has been
shown that this is more robust than other approaches to
dealing with missing data.
Data quality and management
The study will be subject to regular monitoring by the
Clinical Research Associate (CRA), personnel specially
trained in Good Clinical Practice standards. The CRA
will monitor the patient recruitment and ethical issues;
furthermore, he will guarantee the quality of data and
ensure the patient safety. In addition to this, the CRA
will revise the incidence of adverse events and concomi-
tant medication. Data will be evaluated following the
protocol and in concordance with source documents.
Legal and ethical considerations
This clinical trial will comply with the following regu-
lations: the 2008 version of the Declaration of
Helsinki, the Spanish Royal Decree 223/2004 of 6th
February and the recommendations of the Council of
Europe (Good Clinical Practices for Clinical Trials
and Medicinal Products in the European Community,
17th January 1997). The protocol of the clinical trial
has been agreed on by the primary care research
committee, approved by the Clinical Research Ethics
Committee of Jordi Gol i Gurina, which is the refer-
ence committee, and authorized by the Spanish
Agency for Medicaments and Health Products.
Only the researchers involved in the study will have
access to patient codes. In relation to this, we will com-
ply with the Spanish Act 14/2007 of Biomedical Re-
search and Royal Decree 1720/2007 of 21st December
that approves the regulations on the Development of the
Organic Act 15/1999 of 13th December on Personal
Data Protection.
Limitations
The main limitation of the study is that it is an open
trial, since it is not possible to have an effervescent pla-
cebo, but this has been attempted to solve by the blind-
ing of data analysis.
Another limitation is the inability to adjust the results
for dietary salt intake, or exercise, a fact that has been
attempted to solve by explaining and emphasizing the
need not to change lifestyle habits during the study
period.
Discussion
Among the non-pharmacological measures for hyper-
tension treatment, in all existing clinical practice
guidelines it is recommended to reduce salt intake
(25–28), referring to the decline in consumption so-
dium chloride. However, there is controversy over
whether this effect on BP may be produced for any
salt containing sodium. From here, sometimes the
recommendation made is not to reduce salt intake,
but to reduce sodium intake, and this has led to rec-
ommend to hypertensive patients to avoid consuming
effervescent drugs. But, despite the broad recommen-
dation not to use effervescent drugs in patients with
hypertension, there are hardly any studies that show
exactly this pressor effect attributable to sodium in
salt that gives the effervescence of the product. So far
existing trials are quasi-experimental studies with a
Before and After design, where the drugs involved
were not only paracetamol but also ibuprofen or acet-
ylcysteine (14), having some of these drugs already in
itself a pressor effect, or are observational studies
(15), which do not allow establishing a cause and ef-
fect relationship, or are made in laboratory condi-
tions, or are poorly extrapolated to the conditions of
everyday life (16–20). In addition, in some of them it
is not clear whether they have taken into account
some confounding variables, such as the decrease in
pain after the start of analgesic treatment (14).
Although there is a case–control study that evaluates
the effect of effervescent drugs in the risk of developing
cardiovascular events, which results are in favor of in-
creased risk (29), this would be the first clinical trial with
the primary objective of evaluating the effect of efferves-
cent paracetamol in hypertensive patients.
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As it is executed in routine clinical practice, this will
help to extrapolate the results to include the general
population.
The only drugs not allowed are those who already have
a recognized pressor effect as NSAIDs or oral corticoste-
roids. Besides, there is no increase in BP due to changes
in antihypertensive medication because this is an exclu-
sion criterion.
The results will have high validity due to performing
BP measurements not only in consultation, but also
through ABPM, thereby minimizing the possible white
coat effect which could appear with measurements taken
by medical personnel. This is also a relevant difference
with studies already existing.
Trial status
At this time, patient recruitment is proceeding to complete.
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